Buprenorphine’s Schedule 3 status contributes to its increased mobility within and without the therapeutic assemblage. By contrast, methadone’s Schedule 2 status confines it within rela¬tively impervious territories, thereby making it less liable to diversion than buprenorphine. Either buprenorphine is advanced to Schedule 2, or it is destined to be governed as every other Schedule 3 substance. Dr. Adam told me, ‘TFDA knows [about diversion], but it does nothing, because things are complicated. You will need to inventory and count every Schedule 3 medi¬cine, but is this necessary? (Author: They cannot simply focus on buprenorphine.) Right, so this is the problem’.